 Home > Medical News > Latest Medical News > Two styles a day! Hengrui Medicine's anesthetics and eye drops were approved for listing in China today

Two styles a day! Hengrui Medicine's anesthetics and eye drops were approved for listing in China today

 Last Update: 2021-12-08
 Source: Internet
 Author: User

Tags

eye drops poison

positive ion example

biologic medicine

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

ArticleMedicine Guanlan

China's National Food and Drug Administration (NMPA) has announced that Hengrui Medicine's remazolam tosylate for injection has been approved for a new indication

Screenshot source: NMPA official website

Remazolam tosylate: approved the third indication

Remazolam tosylate is a new anaesthetic sedation drug developed by Hengrui Pharmaceuticals.

Remazolam tosylate belongs to the class of benzodiazepines and is a short-acting GABAa receptor agonist

In December 2019, remazolam tosylate was approved for the first time in China for gastroscopy sedation

Screenshot source: Hengrui Medicine's 2021 semi-annual report

Currently, Hengrui Medicine is still exploring more indications for remazolam tosylate

In addition, Hengrui Medicine is also developing clinical studies of remazolam tosylate for ICU sedation, local anesthesia-assisted sedation and other indications, and has submitted a number of new indications for marketing applications for remazolam tosylate

Tafluprost eye drops: urgent clinical need, market shortage

Prostaglandin receptors (PGs) are generally divided into 5 subtypes (DP, EP, FP, IP and TP)

As early as 2015, the original product of tafluprost eye drops from Santen Pharmaceutical, Tepros, was approved for marketing in China

In January 2020, Hengrui Medicine’s tafluprost eye drops submitted a marketing application in China and was accepted.

Screenshot source: CDE official website

Glaucoma is an eye disease characterized by progressive and irreversible vision loss characterized by optic nerve damage

According to reports in the literature, tafluprost is a new generation of PGA drugs.

This time, Hengrui Medicine's tafluprost eye drops have been approved for marketing, and it is hoped that the arrival of this product will bring more treatment options for glaucoma patients

Reference materials:

[1] On November 12, 2021, the drug approval document pending information is released.

[3] Jiangsu Hengrui Pharmaceutical Co.

[4] Zhou Rongyao, Pu Liping, Qing Guoping.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.